Related Experiment Videos
Expression of CD40 has no predictive value in soft tissue sarcomas.
A Ottaiano1, C Pisano, A De Chiara
1Department of Medical Oncology B, National Cancer Institute, G. Pascale, Via M. Semmola, 80131, Naples, Italy. ale.otto@libero.it
Anticancer Research
|June 25, 2003
Summary
CD40 expression in spindle-cell sarcomas does not predict response to epirubicin and ifosfamide chemotherapy. This study found no significant association between CD40 levels and treatment outcomes in sarcoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- CD40, a tumor necrosis factor receptor superfamily member, can induce apoptosis in tumors.
- Proapoptotic receptor expression may enhance chemotherapy-induced apoptosis.
- CD40's role in sarcoma response to chemotherapy requires investigation.
Purpose of the Study:
- To investigate the correlation between CD40 expression in spindle-cell sarcomas and patient response to epirubicin and ifosfamide chemotherapy.
Main Methods:
- Immunohistochemical analysis of CD40 expression in 59 archival sarcoma tissues.
- Tumor response evaluated using World Health Organization (WHO) criteria.
- Chi-square tests used to analyze correlations with chemotherapy response and patient characteristics.
Main Results:
- CD40 was expressed in 42 out of 59 tumors (71%).
- Expression levels varied: <10% in 24%, 10-50% in 27%, and >50% in 20% of tumors.
- No significant association was found between CD40 expression and chemotherapy response or other clinical/pathological features.
Conclusions:
- CD40 expression in spindle-cell soft tissue sarcomas is not associated with response to ifosfamide plus epirubicin chemotherapy.
- The findings do not support CD40 as a predictive biomarker for this specific chemotherapy regimen in sarcomas.